Current best treatment for non-alcoholic fatty liver disease

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 5, 2003, Pages 611-623

  Angulo, Paul ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

tocopherol; Antioxidants; Atorvastatin; Betaine; Derivatives; Diabetes mellitus; Gemfibrozil; Hepatoprotective; Hyperlipidaemia; Insulin resistance; Insulin sensitising; Iron depletion; Metformin; N acetylcysteine; Non alcoholic fatty liver; Non alcoholic steatohepatitis; Obesity; Oxidative stress; Phlebotomy; Pioglitazone; Rosiglitazone; Steatosis; Thiazolidinedione; Troglitazone; Ursodeoxycholic acid; Vatamin E; Vitamin C

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMIODARONE; ANTIOXIDANT; ANTIVIRUS AGENT; ASCORBIC ACID; BETAINE; CALCIUM CHANNEL BLOCKING AGENT; CLOFIBRATE; DIDANOSINE; ESTROGEN DERIVATIVE; FIALURIDINE; GEMFIBROZIL; GLUCOCORTICOID; GLUCOSE; GLUCURONIC ACID; LIPID; METFORMIN; METHOTREXATE; PERHEXILINE MALEATE; PIOGLITAZONE; ROSIGLITAZONE; TAMOXIFEN; TETRACYCLINE; TROGLITAZONE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VALPROIC ACID; ZIDOVUDINE;

ALCOHOL LIVER DISEASE; ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIFESTYLE; LIVER TOXICITY; LIVER TRANSPLANTATION; OBESITY; REVIEW; WEIGHT REDUCTION;

ANTILIPEMIC AGENTS; ANTIOXIDANTS; CHROMANS; CLINICAL TRIALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; EXPERT TESTIMONY; FATTY LIVER; GEMFIBROZIL; HUMANS; LIVER TRANSPLANTATION; OBESITY; THIAZOLES; THIAZOLIDINEDIONES; WEIGHT LOSS;

EID: 0038017098     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.5.611     Document Type: Review

References (81)

1. ANGULO P: Nonalcoholic fatty liver disease. N. Engl. J. Med. (2002) 346:1221-1231.
2. ANGULO P, LINDOR KD: Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue. Gastroenterology (2001) 120:1281-1285.
3. CALDWELL SH, OELSNER DH, IEZZONI JC, HESPENHEIDE EE, BATTLE EH, DRISCOLL CJ: Crytogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. (1999) 29:664-669.
4. RATZIU V, BONYHAY L, DI MARTINO V et al.: Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology (2002) 35:1485-1493.
5. BUGIANESI E, LEONE N, VANNI E et al.: Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology (2002) 123:134-140.
6. LEE RG: Nonalcoholic steatohepatitis. A study of 49 patients. Hum. Pathol. (1989) 20:594-599.
7. POWELL EE, COOKSLEY WG, HANSON R, SEARLE J, HALLIDAY JW, POWELL LW: The natural history of nonalcoholic steatohepatitis: a follow up study of forty-two patients for up to 21 years. Hepatology (1990) 11:74-80.
8. BACON BR, FARAHVASH MJ, JANNEY CG, NEUSCHWANDER-TETRI BA: Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology (1994) 107:1103-1109.
9. TELI M, OLIVER FW, BURT AD, BENNET MK, DAY CP: The natural history of nonalcoholic fatty liver: a follow up study. Hepatology (1995) 22:1714-1717.
10. MATTEONI CA, YOUNOSSI ZM, GRAMLICH TL et al.: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 116:1413-1419.
11. RATZIU V, GIRAL P, CHARLOTTE F et al.: Liver fibrosis in overweight patients. Gastroenterology (2000) 118:1117-1123.
12. ANGULO P, LINDOR KD: Treatment of nonalcoholic fatty liver: present and emerging therapies. Sem Liver Dis (2001) 21:81-88.
13. ANGULO P, LINDOR KD: Treatment of non-alcoholic steatohepatitis. Best Pract. Res. Clin. Gastroenterol. (2002) 16:797-810.
14. ANGULO P, KEACH JC, BATTS KP, LINDOR KD: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology (1999) 30:1356-1362.
15. DIEHL AM, GOODMAN Z, ISHAK KG: Alcohol-like liver disease in nonalcoholic. A clinical and histological comparison with alcohol-induced liver injury. Gastroenterology (1989) 95:1056-1060.
16. ERIKSSON S, ERIKSSON KF, BONDESSON L: Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med. Scand (1986) 220:83-88.
17. ROZENTAL P, BIAVA C, SPENCER H et al.: Liver morphology and function tests in obesity and during total starvation. Am. J. Dig. Dis. (1967) 12:198-208.
18. DRENICK EJ, SIMMONS F, MURPHY J: Effect on hepatic morphology of treatment of obesity by fasting, reducing diets, and small bowel bypass. N. Engl. J. Med. (1970) 282:829-834.
19. PALMER M, SCHAFFNER F: Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology (1990) 99:1408-1413.
20. ANDERSEN T, GLUUD C, FRANZMANN MB, CHRISTOFFERSEN P: Hepatic effects of dietary weight loss in morbidly obese patients. J. Hepatol. (1991) 12:224-229.
21. UENO T, SUGAWARA H, SUJAKU K et al.: Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J. Hepatol. (1997) 27:103-107.
22. VAJRO P, FONTANELLA A, PERNA C, ORSO G, TEDESCO M, DE VICENZO A: Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J. Pediatr. (1994) 125:239-241.
23. FRANZESE A, VAJRO P, ARGENZIANO A et al.: Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig. Dis. Sci. (1997) 42:1428-1432.
24. RASHID M, ROBERTS E: Nonalcoholic steatohepatitis in children. J. Pediat. Gastroenterol. Nut. (2000) 30:48-53.
25. Anonymous: Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch. Intern. Med. (1998) 158:1855-1867.
26. KRAUS RM, ECKEL RH, HOWARD B et al.: AHA dietary guidelines: revision 2000. A statement for health care professionals from the nutrition committee of the American Heart Association. Stroke (2000) 31:2751-2766.
27. CLARK MJ JR, STERRETT JJ, CARSON DS: Diabetes guidelines: a summary and comparison of the recommendations of the American Diabetes Association, Veterans Health Administration, and American Association of Clinical Endocrinologists. Clin. Ther. (2000) 22:899-910; Discussion 898.
28. FERNANDEZ MI, TORRES MI, RIOS A. Steatosis and collagen content in experimental liver cirrhosis are affected by dietary monounsaturated and polyunsaturated fatty acids. Scand. J. Gastroenterol. (1997) 32:350-356.
29. FERNANDEZ-LOPEZ JA, REMESAR X, FOZ M, ALEMANY M: Pharmacological approaches for the treatment of obesity. Drugs (2002) 62:915-944.
30. DEWIND LT, PAYNE JH: Intestinal bypass surgery for morbid obesity. Long term results. JAMA (1976) 236:2298-2301.
31. CAMPBELL JM, HUNG TK, KARAM JH, FORSHAM PH: Jejunoileal bypass as a treatment of morbid obesity. Arch. Intern. Med. (1977) 137:602-610.
32. ACKERMAN NB: Protein supplementation in the management of degenerating liver function after jejunoileal bypass. Surg. Gynecol. Obstet. (1979) 149:8-14.
33. DRENICK EJ, FISLER J, JOHNSON D: Hepatic steatosis after intestinal bypass. Prevention and reversal by metronidazol, irrespective of protein-calorie malnutrition. Gastroenterology (1982) 82:535-548.
34. BUCHMAN AL, DUBIN M, JENDEN D et al.: Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition in rats. Gastroenterology (1992) 102:1363-1370.
35. BUCHMAN AL, DUBIN MD, MOUKARZEL AA et al.: Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline Supplementation. Hepatology (1995) 22:1390-1403.
36. PAPPO I, BECOVIER H, BERRY EM, FREUD HR: Polymixin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in rat. J. Sur. Res. (1991) 51:106-112.
37. FREUD HR, MUGGIA-SULLAN M, LAFRANCE R, ENRIONE EB, POPP MB, BJORNSON HS: A possible beneficial effect of metronidazol in reducing TPN-associated liver function derangements. J. Sur. Res. (1985) 38:356-363.
38. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. Diabetes prevention program research group. N. Engl. J. Med. (2002) 346:393-403.
39. LIN HZ, YANG SQ, CHUCKAREE C, KUHAJDA F, RONNET G, DIEHL AM: Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat. Med. (2000) 6:998-1003.
40. ASSY N, KAITA K, MYMIN D, LEVY C, ROSSER B, MINUK G: Fatty infiltration of liver in hyperlipidemic patients. Dig. Dis. Sci. (2000) 45:1929-1934.
41. DAY C: Thiazolidinediones: a new class of antidiabetic drugs. Diabet. Med. (1999) 16:179-192.
42. CALDWELL SH, HESPENHEIDEN EE, REDICK JA, IEZZONI JC, BATTLE EH, SHEPPARD BL: A pilot study of thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am. J. Gastroenterol. (2001) 96:519-525.
43. WATKINS PB, WHITCOMB RW: Hepatic dysfunction associated with troglitazone. N. Engl. J. Med. (1998) 338:908-909.
44. NEUSCHWANDER-TETRI BA, BRUNT EM, BACON BR et al.: Histological improvement in NASH following reduction of insulin resistance with 48-week treatment with the PPAγ agonist rosiglitazone. Hepatology (2002) 36:379A (Abtract).
45. ACOSTA RC, MOLINA EG, O'BRIEN CB et al.: The use of pioglitazone in nonalcoholic steatohepatitis. Gastroenterology (2001) 120(Suppl.):2778 (Abstract).
46. SANYAL AJ, CONTOS MJ, SARGEANT C et a.: A randomized controlled pilot study or pioglitazone and vitamin E versus vitamin E for nonalcoholic steatohepatitis. Hepatology (2002) 36:382A (Abstract).
47. MARCHESINI G, BRIZI M, BIANCHI G et al.: Metformin in non-alcoholic steatohepatitis. Lancet (2001) 358:893-894.
48. NAIR S, DIEHL AM, PERRILLO R: Metformin in nonalcoholic steatohepatitis (NASH): efficacy and safety: a preliminary report. Gastroenterology (2002) 122(Suppl.):4 (Abstract).
49. HOUGLUM K, VENKATARAMANI A, LYCHE K, CHOJKIER M: A pilot study of the effects of d-α-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology (1997) 113:1069-1073.
50. LAVINE JE: Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J. Pediat. (2000) 136:734-738.
51. HASEGAWA T, YONEDA M, NAKAMURA K, MAKINO I, TERANO A: Plasma transforming growth factor-β1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment. Pharmacol. Ther. (2001) 15:1667-1672.
52. HARRISON SA, KADAKIA S, TORGERSON S et al.: Vitamin E and vitamin C in the treatment of nonalcoholic steatohepatitis. A prospective, randomized, placebo-controlled clinical trial. A preliminary report. Gastroenterology (2002) 122(Suppl.):M1332 (Abstract).
53. BARAK AJ, BECKENHAUER HC, JUNNILA M, TUMA DJ: Dietary betaine promotes generation of hepatitic S-adenosylmethionine and protects the liver from ethanol-induced fatty infiltration. Alcohol. Clin. Exp. Res. (1993) 17:552-555.
54. ABDELMALEK M, ANGULO P, JORGENSEN RA, SYLVESTRE P, LINDOR KD: Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am. J. Gastroenterol. (2001) 96:2711-2717.
55. MIGLIO F, ROVATI LC, SANTORO A, SETKIKAR I: Efficacy and safety of oral betaine glucurontae in nonalcoholic steatohepatitis. Arzneim. Forsch. (2000) 50(2):722-727.
56. GULBAHAR O, KARASU ZA, ERSOZ G, AKARCA US, MUSOGLU A: Treatment of non-alcoholic steatohepatitis with N-acetylcysteine. Gastroenterology (2000) 118(Part 2 Suppl.):6550 (Abstract).
57. DESAI TK: Phlebotomy reduces transaminase levels in patients with chronic non-viral non-alcoholic steatohepatitis Hepatology (1996) 24(Part 2 Suppl.):1498 (Abstract).
58. DESAI TK: Phlebotomy reduces transaminase levels in patients with non-alcoholic steatohepatitis. Gastroenterology (2000) 118(Part 1 Suppl. 2):1071 (Abstract).
59. NITECKI J, JACKSON FW, ALLEN ML, FARR VL, JACKSON FW: Effect of phlebotomy on non-alcoholic steatohepatitis (NASH). Gastroenterology (2000) 118(Part 2 Suppl. 2):6679 (Abstract).
60. FACCHINI FS, HUA NW, STOOHS RA: Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology (2002) 122:931-939.
61. LAURIN J, LINDOR KD, CRIPPIN JS et al.: Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol-induced steatohepatitis: A pilot study. Hepatology (1996) 23:1464-1467.
62. BASARANOGLU M, ACBAY O, SONSUZ A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J. Hepatol. (1999) 31:384.
63. HORLANDER JC, KWO PY, CUMMINGS OW, KOUKOULIS G: Atorvastatin for the treatment of NASH. Gastroenterology (2001) 120(Suppl.):2767 (Abstract).
64. ANGULO P: Use of ursodeoxycholic acid in patients with liver disease. Current Gastrioenterol. Rep. (2002) 4:37-44.
65. KOBAK GE, DEUTSCH G, DAHL R, DEVEREAUX MW, GUMPRICHT E, SOKOL RJ: Fat-laden hepatocytes are more prone to cellular necrosis than apoptosis when exposed to hydrophobic bile acids. Gastroenterology (2002) 122(Suppl. 1):411.
66. GUMA C, VIOLA L, THOME M, GALDAME O, ALVAREZ E: Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: results of a prospective clinical controlled trial. Hepatology (1997) 26(Part 2 Suppl.):1036 (Abstract).
67. CERIANI R, BUNATI S, MORINI L, SACCHI E, COLOMBO G: Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis. Hepatology (1998) 28(Part 2 Suppl.):894 (Abstract).
68. HOLOMAN J, GLASA J, KASAR J et al.: Serum markers of liver fibrosis in patients with non-alcoholic steatohepatitis (NASH). Correlation to liver morphology and effect of therapy. J. Hepatol. (2000) 32(Suppl. 2):210 (Abstract).
69. VAJRO P, FRANZE A, VALERIO G, IANNUCCI MP, ARAGIONE N: Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J. Pediatr. (2000) 136:739-743.
70. CHARLTON M, KASPAROVA P, WESTON S et al.: Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl. (2001) 7:608-614.
71. CONTOS MJ, CALES W, STERLING RK et al.: Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl (2001) 7:363-373.
72. LETTERSON P, FROMENTY B, TERRIS B, DEGOTT C, PASSAYRE D: Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J. Hepatol. (1996) 24:200-208.
73. WELTMAN MD, FARRELL GC, LIDDLE C: Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology (1996) 111:1645-1653.
74. LECLERCQ IA, FARRELL GC, FIELD J, BELL DR, GONZALEZ FJ, ROBERTSON GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J. Clin. Invest. (2000) 105:1067-1075.
75. WELTMAN MD, FARREL GC, HALL P, INGELMAN-SUNDBERG M, LIDDLE C: Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology (1998) 27:128-133.
76. YANG SQ, LIN HZ, LANE MD, CLEMENS M, DIEHL AM: Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc. Natl. Acad. Sci. USA (1997) 94:2557-2562.
77. LI Z, YANG S, LIN H et al.: Probiotics and antibodies to TNF inhibits inflammatory activity and improves nonalcoholic fatty liver disease. Hepatology (2003) 37:343-350.
78. CHAVIN KD, YANG SQ, LIN HZ et al.: Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J. Bio. Chem. (1999) 274:5692-5700.
79. CORTEZ-PINTO H, CHATHAM J, CHACKO VP, ARNOL C, RASHID A, DIEHL AM: Alterations in liver ATP homeostasis in human nonalcoholic steatoheaptitis. A pilot study. JAMA (1999) 282:1659-1664.
80. TALWALKAR J, KEACH J, ANGULO P, LINDOR KD: Health-related quality of life assessment in nonalcoholic steatohepatitis. Hepatology (2001) 34(Suppl.):309A (Abstract).
81. TALWALKAR AJ, DONLINGER JJ, GOSSARD AA, LINDOR KD: Health state preferences among patients with nonalcoholic steatohepatitis. Hepatology (2002) 36(Suppl.):382A (Abstract).